NCT07868666Recruiting
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes
Clinical Decision Support for SGLT2i After AKI in Type 2 Diabetes Pilot Study
Source: ClinicalTrials.gov · Last updated 4 Nov 2026
Brief summary (registry, in English)
This pilot study will evaluate the feasibility of using a clinical decision support(CDS) message to support consideration of SGLT2 inhibitor prescribing in patients with type 2 diabetes who recently had acute kidney injury. Participating M Health Fairview primary care clinics will be randomized to either receive the clinical decision support intervention or continue usual care. In intervention clinics, providers or clinic pharmacists will receive a message before a scheduled encounter with an eligible patient. The message is intended to support clinical decision-making about SGLT2 inhibitor use, but prescribing decisions will remain with the patient's usual clinical care team. The study will assess feasibility outcomes, including identification of eligible patients, delivery of clinical decision support (CDS) messages, provider/pharmacist receipt of CDS messages, SGLT2i consideration, SGLT2i prescribing, and availability of follow-up kidney function data in the electronic health record.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 5 Oct 2026
- Start date
- 2 Nov 2026
- Primary completion date
- 31 Oct 2032
- Lead sponsor
- University of Minnesota
- Diseases
- Chronic kidney disease, Type 2 diabetes
- NCT number
- NCT07868666
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 2 Nov 2026 to the primary completion date, 31 Oct 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Medical history in the prior 1 year of indwelling Foley urinary catheter, cystitis, pyelonephritis, prostatitis, or urinary tract infection (by billing code)
Other illness
- History of kidney transplantation as a recipient(by billing code)
- SGLT2i allergy in the EHR allergy list
- Medical history of diabetic ketoacidosis, dementia, hospice care, or oncology care (by billing code and/or encounter)
Lab values
- Serum creatinine rise of at least 0.3 mg/dL between the two most recent serum creatinine measurements
Other
- None
- Opted out of research use of AHC/M Health Fairview data shelter data
- Pregnancy documented in AHC/M Health Fairview data shelter data (by billing code)
- Children
- Prisoners
Who the study is looking for
- Assigned to work in a primary care specialty as a medical provider or assigned to work as a clinic pharmacist
- Assigned to work in one of the participating study clinics
- Scheduled to be seen in a participating clinic with a physician or advanced practice provider in a primary care specialty or a clinic pharmacist
- Medical history of acute kidney injury during a hospitalization with discharge within 1 year before the scheduled appointment
- Medical history of type 2 diabetes mellitus (by billing code)
- Age 30 to 75 years at the date of study enrollment
- Available eGFR from labs more than 3 business days before the scheduled appointment and after AKI onset that is at least 30 mL/min/1.73 m²
- Either a serum creatinine lab measured after discharge from the hospitalization including the AKI, or the last serum creatinine lab during the hospitalization with AKI is less than 0.3 mg/dL above the patient's baseline serum creatinine concentration
Age in the registry: 30 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.